【Abstract】Objective To assess the value of 99Tcm-tetrofosmin imaging in discriminating malignant mass from benign breast mass.Methods From June 2000 to January 2002, 104 patients with breast mass detected by clinical examination were included. After 740 MBq 99Tcm-tetrofosmin was injected intravenously in the contralateral arm to the breast lesion, the front and the lateral images were collected in 5 min, 10 min and 20 min respectively. 99Tcm-tetrofosmin imaging localized in breast was defined as the positive sign of affinitive tumor. All patients underwent operation within one week. Using histological assessment as a golden standard, the sensitivity, specificity, positive and negative predictive value for 99Tcm-tetrofosmin SPECT of the breast were calculated respectively. Results The sensitivity of 99Tcm-tetrofosmin imaging for discriminating between malignant mass and benign mass in palpable breast lesions was 87%, specificity 84%, positive and negative predictive value were 85% and 86% respectively. Conclusion The results suggested that 99Tcm-tetrofosmin imaging is a valuable tool for distinguishing between malignant mass and benign mass in palpable breast lesions.
Citation：
ZHOU Leilei,SONG Wenzhong,CHEN Mingxi,LIU Jinping,HUANG Jin,XIE Hongjun,WANG Xiaodong,LUO Jing.. A Clinical Study about 99Tcm-Tetrofosmin Imaging in Detection of Suspicious Palpable Breast Lesions. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2005, 12(6): 609-611. doi:
Copy
| 1. |
1 Kerlikowske K, Grady D, Barclay J, et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography
[Ｊ]. JAMA, 1996; 276(1)332 中华人民共和国卫生部医政司. 核医学诊断与治疗规范 [S]. 第1版.北京: 中国科学技术出版社, 1997241~2423 Taillefer R. The role of 99Tcmsestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis [Ｊ]. Semin Nucl Med, 1999; 29(1)164 章斌.99mTetetrofosmin 在乳腺癌及其转移灶显像中的应用[Ｊ]. 国外医学放射医学核医学分册, 2001; 25(1)125 de Jong M, Bernard BF, Breeman WA, et al. Comparison of uptake of 99mTcMIBI, 99mTctetrofosmin and 99mTcQ12 into human breast cancer cell lines [Ｊ]. Eur J Nucl Med, 1996; 23(10)13616 唐谨. 核素乳腺显像的现状和今后工作的思考 [Ｊ]. 中华核医学杂志，1997; 17(1)697 Mansi L, Rambaldi PF, Cuccurullo V, et al. Diagnostic and prognostic role of 99mTctetrofosmin in breast cancer [Ｊ]. Q J Nucl Med, 1997; 41(3)2398 Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with technetium99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases [Ｊ]. Eur J Nucl Med, 1996; 23(8)9329 宋文忠,周蕾蕾,陈明曦，等. 99mTetetrofosmin 显像对乳腺癌及腋窝淋巴结转移诊断价值评价 [Ｊ]. 中国医学影像技术, 2003； 19(11)153110 Obwegeser R, Berghammer P, MuellauerErtl S, et al. 99mTctetrofosmin scintigraphy for the evaluation of suspicious palpable and nonpalpable breast lesions [Ｊ]. Breast Cancer Res Treat, 2000; 62(3)253.
|
- 1. 1 Kerlikowske K, Grady D, Barclay J, et al. Effect of age, breast density, and family history on the sensitivity of first screening mammography
[Ｊ]. JAMA, 1996; 276(1)332 中华人民共和国卫生部医政司. 核医学诊断与治疗规范 [S]. 第1版.北京: 中国科学技术出版社, 1997241~2423 Taillefer R. The role of 99Tcmsestamibi and other conventional radiopharmaceuticals in breast cancer diagnosis [Ｊ]. Semin Nucl Med, 1999; 29(1)164 章斌.99mTetetrofosmin 在乳腺癌及其转移灶显像中的应用[Ｊ]. 国外医学放射医学核医学分册, 2001; 25(1)125 de Jong M, Bernard BF, Breeman WA, et al. Comparison of uptake of 99mTcMIBI, 99mTctetrofosmin and 99mTcQ12 into human breast cancer cell lines [Ｊ]. Eur J Nucl Med, 1996; 23(10)13616 唐谨. 核素乳腺显像的现状和今后工作的思考 [Ｊ]. 中华核医学杂志，1997; 17(1)697 Mansi L, Rambaldi PF, Cuccurullo V, et al. Diagnostic and prognostic role of 99mTctetrofosmin in breast cancer [Ｊ]. Q J Nucl Med, 1997; 41(3)2398 Mansi L, Rambaldi PF, Procaccini E, et al. Scintimammography with technetium99m tetrofosmin in the diagnosis of breast cancer and lymph node metastases [Ｊ]. Eur J Nucl Med, 1996; 23(8)9329 宋文忠,周蕾蕾,陈明曦，等. 99mTetetrofosmin 显像对乳腺癌及腋窝淋巴结转移诊断价值评价 [Ｊ]. 中国医学影像技术, 2003； 19(11)153110 Obwegeser R, Berghammer P, MuellauerErtl S, et al. 99mTctetrofosmin scintigraphy for the evaluation of suspicious palpable and nonpalpable breast lesions [Ｊ]. Breast Cancer Res Treat, 2000; 62(3)253.
